Predict your next investment

Pixalere company logo
INTERNET | Internet Software & Services / Healthcare
pixalere.com

See what CB Insights has to offer

Founded Year

2006

About Pixalere

Pixalere is a cloud-based wound management system that allows clinicians and administrators to better care for people with complex chronic wounds. It is an evidence-based electronic solution providing better outcomes through clinical collaboration, and best practice wound care.

Pixalere Headquarter Location

Canada

866-297-2442

Latest Pixalere News

Sanara MedTech : Announces Second Quarter 2021 Results and Business Update

Aug 16, 2021

08/16/2021 | 05:53pm EDT Message : Home » News » Sanara MedTech Inc. Announces Second Quarter 2021 Results and Business Update August 16, 2021 FORT WORTH, TX / ACCESSWIRE / Aug 16, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ('Sanara,' the 'Company,' 'we,' 'our' or 'us') (NASDAQ: SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today its strategic, operational and financial results for the quarter ended June 30, 2021. Ron Nixon, Sanara's Executive Chairman, stated, 'Sanara had another record sales quarter to end the first half of 2021. Our results were driven by strong product sales across a wider number of facilities and geographies. Additionally, we continued to execute on our comprehensive wound and skin strategy by closing on the Pixalere partnership, arranging pilots to prove the value of the Company's offering, and continuing to focus on developing new products. Subsequent to the end of the quarter we completed our acquisition of certain assets of Rochal Industries, LLC ('Rochal') and brought their team in-house, which we believe will contribute to our long-term success.' Second Quarter 2021 Strategic Highlights The Company announced an exclusive partnership with Pixalere Healthcare Inc. ('Pixalere') to advance its comprehensive wound and skin care strategy. This partnership combines Pixalere's technology, including decision support, documentation, and wound tracking analytics, with complementary Sanara solutions that offer virtual access to expert wound and skin physicians/clinicians, advanced diagnostics, and wound care product order fulfillment. The Company's surgical products continued to be approved for use in additional facilities throughout the quarter. As of June 30, 2021, CellerateRX was approved to be used in over 900 hospitals and ambulatory surgical centers. Sanara hired 8 additional salespeople in Q2, bringing the total number of regional sales managers and territory managers to 26. The Company's surgical products generated revenue in 21 states in Q2 2021 at or above a $50,000 annual run rate (compared to 18 states that generated revenue above $50,000 for the full year 2020). For the first half of the year, CellerateRX Surgical has been sold in over 300 hospitals/ASCs as of June 30, 2021 Subsequent to the end of the quarter, the Company announced the acquisition of certain assets of Rochal. In connection with this acquisition, Sanara brought in-house a dedicated research and development team that the Company believes can develop products uniquely suited to address patients' wound and skin conditions. The addition of the Rochal team also strengthens Sanara's expertise in areas of regulatory, compliance, manufacturing, and quality control and aligns the long-term interests of both companies. Second Quarter and First Half 2021 Consolidated Financial Results Revenues. For the three months ended June 30, 2021, we generated revenues of $6,277,133 compared to revenues of $2,967,183 for the three months ended June 30, 2020, representing a 112% increase from the prior year period. For the six months ended June 30, 2021, revenues totaled $11,286,569 compared to revenues of $6,491,514 for the six months ended June 30, 2020, representing a 74% increase from the prior year period. The higher revenues in 2021 were primarily due to increased sales of surgical wound care products as a result of our sales force expansion last year and our continuing strategy to expand our independent distribution network in both new and existing U.S. markets. In addition, revenues in the second quarter of 2020 were negatively impacted due to the suspension of elective surgeries and restricted access to patient facilities throughout most parts of the United States as a result of the COVID­19 pandemic. Cost of goods sold. Cost of goods sold for the three months ended June 30, 2021, was $536,405, compared to Cost of goods sold of $348,675 for the three months ended June 30, 2020. Cost of goods sold for the six months ended June 30, 2021 was $1,010,838, compared to Cost of goods sold of $678,863 for the six months ended June 30, 2020. The increase over the prior year period was primarily due to higher sales volume. Selling, general and administrative expenses. SG&A expenses for the three months ended June 30, 2021, were $6,562,144, as compared to $3,582,511 for the three months ended June 30, 2020. SG&A expenses for the six months ended June 30, 2021, were $11,971,874 compared to SG&A expenses of $8,514,662 for the six months ended June 30, 2020. The higher SG&A expenses in 2021 were primarily due to increased payroll costs resulting from sales force expansion and operational support, and higher sales commission expense as a result of higher product sales. As part of our strategy to expand our sales reach in new and existing markets, we employed eight additional field sales managers during the first half of 2021. As of June 30, 2021, we had a total of 26 field sales managers. Net income / loss. We had a net loss of $1,205,973 for the three months ended June 30, 2021, compared to net loss of $1,129,557 for the three months ended June 30, 2020. For the six months ended June 30, 2021, we had a net loss of $2,389,349, compared to net loss of $2,970,569 for the six months ended June 30, 2020. The improvement in our net loss for the six months ended June 30, 2021 was primarily due to higher sales revenues in 2021 compared to the same period in 2020. The Company will host a conference call on Tuesday, August 17, 2021, at 9:00 a.m. Eastern Time. The toll-free number to call for this teleconference is 844-407-9500 (international callers: 862-298-0850). A telephonic replay of the conference call will be available through Tuesday, August 31, 2021, by dialing 877-481-4010 (international callers: 919-882-2331) and entering the replay passcode: 42396. A live webcast of the conference call will be available under the Investor Relations section of the Company's website, www.SanaraMedTech.com. A one-year online replay will be available after the conclusion of the live broadcast. About Sanara MedTech Inc. With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets, distributes, and develops wound and skincare products for use by physicians and clinicians in hospitals, clinics, and all post-acute care settings and is seeking to offer wound care and dermatology virtual consultation services via telemedicine. Sanara's products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgical Activated Collagen® to the surgical markets as well as the following products to the wound care market: BIAKŌS™ Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS™ Antimicrobial Skin and Wound Irrigation Solution and HYCOL™ Hydrolyzed Collagen. Through the Rochal asset acquisition, Sanara's pipeline now contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement, and cell compatible substrates. The Company believes it has acquired the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skincare for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of the healthcare industry. For more information, visit SanaraMedTech.com. Information about Forward-Looking Statements The statements in this press release that do not constitute historical facts are 'forward-looking statements,' within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as 'anticipate,' 'believes,' 'contemplates,' 'continue' 'could,' 'estimates,' 'expect,' 'intend,' 'may,' 'plan,' 'potential' 'predicts,' 'preliminary,' 'project,' 'seek,' 'should,' 'target,' 'will,' or 'would,' or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include statements regarding anticipated benefits of the Rochal acquisition, the development of new products and expansion of the Company's business in telehealth and wound care. These items involve risks, contingencies and uncertainties such as Sanara's ability to successfully integrate the acquired business and operations of Rochal, including Sanara's ability to retain key employees following the acquisition, unexpected costs or expenses that may result from the acquisition, uncertainties associated with the development and process for obtaining regulatory approval for new products, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws. Investor Contact: 713-826-0524

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Pixalere Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pixalere Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.